A first-in-human (FIH) study of RJVA-001 in Type 2 Diabetes (T2D)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Mar 2025 According to a Fractyl Health media release, submission of the first CTA module for RJVA-001 in T2D to the regulatory authorities in 1H 2025, and if the CTA is authorized, the company expects to report preliminary data in 2026.
31 Jan 2025 According to a Fractyl Health media release, Company is on track to initiate first-in-human studies for RJVA-001 in H1 2025.
12 Nov 2024 According to a Fractyl Health media release, company is finalizing key in vivo studies to support the Clinical Trial Application (CTA) submission for RJVA-001 in T2D.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com